RAMB - DEZEMBRO

89 / 96

The role of regulatory T cells , interleukin-10 and in vivo scintigraphy in autoimmune and idiopathic diseases – Therapeutic perspectives and prognosis
Rev Assoc Med B ras 2017; 63(12):1090-1099 1099
31. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human
anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and
apoptosis-prone population. Eur J Immunol. 2001; 31(4):1122-31.
32. Wing K, Ekmark A, Karlsson H, Rudin A, Suri-Payer E. Characterization of
human CD25+ CD4+ T cells in thymus, cord and adult blood. Immunology.
2002; 106(2):190-9.
33. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban
PC, et al. Human CD25+CD4+ T suppressor cell clones produce transforming
growth factor beta, but not interleukin 10, and are distinct from type 1 T
regulatory cells. J Exp Med. 2002; 196(10):1335-46.
34. Fontenot JD, GavinMA, Rudensky AY. Foxp3 programs the development and
function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6.
35. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A,
Expression of interleukin (IL)-2 and IL-7 receptors discriminates
between human regulatory and activated T cells. J Exp Med. 2006;
203(7):1693-700.
36. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky
AY. Regulatory T cell lineage specification by the forkhead transcription
factor foxp3. Immunity. 2005; 22(3):329-41.
37. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression
inversely correlates with FoxP3 and suppressive function of human CD4+
T reg cells. J Exp Med. 2006; 203(7):1701-11.
38. Möttönen M, Heikkinen J, Mustonen L, Isomäki P, Luukkainen R, Lassila
O. CD4+ CD25+ T cells with the phenotypic and functional characteristics
of regulatory T cells are enriched in the synovial fluid of patients with
rheumatoid arthritis. Clin Exp Immunol. 2005; 140(2):360-7.
39. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)
CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence,
phenotype, and function between peripheral blood and synovial fluid.
Arthritis Rheum. 2004; 50(9):2775-85.
40. Cao D, Malmström V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C.
Isolation and functional characterization of regulatory CD25brightCD4+
T cells from the target organ of patients with rheumatoid arthritis. Eur J
Immunol. 2003; 33(1):215-23.
41. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V.
CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients
with chronic rheumatic disease. Arthritis Res Ther. 2004; 6(4):R335-46.
42. Cao D, Börjesson O, Larsson P, Rudin A, Gunnarsson I, Klareskog L, et al.
FOXP3 identifies regulatory CD25bright CD4+ T cells in rheumatic joints.
Scand J Immunol. 2006; 63(6):444-52.
43. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al.
Compromised function of regulatory T cells in rheumatoid arthritis and
reversal by anti-TNFalpha therapy. J Exp Med. 2004; 200(3):277-85.
44. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR.
Interleukin-17-producing T cells are enriched in the joints of children with
arthritis, but have a reciprocal relationship to regulatory T cell numbers.
Arthritis Rheum. 2008; 58(3):875-87.
45. van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW,
Lafeber FP, et al. Proinflammatory mediator-induced reversal of CD4+,CD25+
regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis
Rheum. 2007; 56(3):732-42.
46. Falcão PL, Malaquias LC, Martins-Filho OA, Silveira AM, Passos VM, Prata
A, et al. Human Schistosomiasis mansoni: IL-10 modulates the in vitro
granuloma formation. Parasite Immunol. 1998; 20(10):447-54.
47. Bacchetta R, Gambineri E, Roncarolo MG. Role of regulatory T cells and
FOXP3 in human diseases. J Allergy Clin Immunol. 2007; 120(2):227-35.
48. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al.
The features of myasthenia gravis with autoantibodies to MuSK. J Neurol
Neurosurg Psychiatry. 2005; 76(8):1099-102.
49. Qureschi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM,
et al. Plasma exchange versus intravenous immunoglobulin treatment in
myasthenic crisis. Neurology. 1999; 52(3):629-32.
50. Rønager J, Ravnborg M, Hermansen I, Vosrstrup S. Immunoglobulin
treatment versus plasma exchange in patients with chronic moderate to
severe myasthenia gravis. Artif Organs. 2001; 25(12):967-73.
51. Myasthenia Gravis Clinical Study Group. A randomized clinical trial comparing
prednisone and azathioprine in myasthenia gravis. Results of the second
interim analysis. J Neurol Neurosurg Psychiatry. 1993; 56(11):1157-63.
52. Falcão PL. Método e usos da técnica de citometria de fluxo para controle e
acompanhamento de lesões musculares em atletas submetidos a esforço físico;
abordagem imunológica e condicionamento físico. INPI. 2002, PI0206722-6.
53. Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with
methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;
97(6):370-3.
54. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of
prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia
Gravis Study Group. Neurology. 1998; 50(6):1778-83.
55. Evoli A, Batocchi AP, Palmisani MT, Lo Monaco ML, Tonali P. Long-term
results of corticosteroid therapy in patients with myasthenia gravis. Eur
Neurol. 1992; 32(1):37-43.
56. Pereira ALC, Bolzani FCB, StefaniM, CharlínR. Uso sistêmico de corticosteróides:
revisão da literatura. Med Cutan Iber Lat Am. 2007; 35(1):35-50.
57. Signore A, Soroa VA, De Vries EF. Radiobelled white blood cells or FDG for
imaging of inflammation and infection? Q J Nucl Med Mol Imaging. 2009;
53(1):23-5.
58. Becker W, Meller J. The role of nuclear medicine in infection and inflammation.
Lancet Infect Dis. 2001; 1(5):326-33.
59. Imam SK, Lin P. Radiotracers for imaging of infection and inflammation:
a review. World J Nucl Med. 2006; 5(1):40-55.
60. Gemmel F, Dumarey N, Welling M. Future diagnostic agents. Semin Nucl
Med. 2009; 39(1):11-26.
61. Rennen HJJM, Boerman OC, Oyen WJG, Corstens FHM. Scintigraphy
imaging of inflammatory processes. Curr Med Chem. 2002; 1(1):63-75.
62. Brasileiro CB, Cardoso VN, Ruckert B, Campos TPR. Avaliação de processos
inflamatóriosnaarticulaçãotemporomandibularempregandoleucócitosautólogos
marcados com tecnécio-99memmodelo animal. Radiol Bras. 2006; 39(4):283-6.
63. Brasileiro CB, Pacheco CM, Queiroz-Junior CM, Lima CF, Silva JB, Campos TP.
(99m)Tc-labeled-1-thio-beta-d-glucose as a new tool to temporomandibular
joint inflammatory disorders diagnosis. Appl Radiat Isto. 2010; 68(12):2261-7.
64. Campos TPR, Brasileiro CB, MaiaMJO. Radiofármaco e suas composições para
cintilografia de sítios inflamatórios e infecciosos. INPI 2010, PI0904754-9.
65. Maia MJO, Campos TPR. Síntese e caracterização do 99mTc-5-thio-d-glicose
para SPECT. In: Anais do 21 CBEB2008. Rio de Janeiro: SBEB; 2008. v. 1, p. 1-8.
66. Dalmázio I, Campos TPR. Compostos de coordenação metal-sacarídeo para
terapia e diagnóstico. INPI 2010, PI1005216-0.
67. Kaneyama K, Segami NT, Sun W, Sato J, Fujimura K. Analysis of tumor
necrosis factor-α, interleukin-6, interleukin-1β, soluble tumor necrosis
factor receptors I e II, interleukin-6 soluble receptor, interleukin-1 soluble
receptor type II, interleukin-1 receptor antagonist, and protein in the synovial
fluid of patients with temporomandibular joint disorders. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 2005; 99(3):276-84.
68. Sukedai M, Tominaga K, Habu M, Matsukawa A, Nishihara T, Fukuda J.
Involvement of tumor necrosis factor-alpha and interleukin-8 in antigen-
induced arthritis of the rabbit temporomandibular joint. J Oral Pathol Med.
2004; 33(2):102-10.
69. Rennen HJ, Boerman OC, Oyen WJ, Corsten FH. Kinetics of 99m Tc-labeled
interleukin-8 in experimental inflammation and infection. J Nucl Med. 2003;
44(9):1502-9.